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The relationship between molecular abnormalities and neoplasm
has been extensively reviewed and there is strong evidence that
abnormalities of p53 gene represent the most common molecular
change in human cancer. Such abnormalities can be detected in a
number of ways. Several prior studies have revealed p53 protein
expression via immunohistochemistry (IHC) in 42—69% of
colorectal cancers (Scott et al, 1991; Auvinen et al, 1994).
However, the prognostic value of this protein remains to be
defined, probably due to variability of detection and retrieval
systems (Wynford-Thomas, 1994). To be clinically useful, prog-
nostic markers should be accessible to analysis with simple and
reproducible procedures appropriate for routine use. We have
adapted the recently developed luminometric immunoassay (LIA)
(Borg et al, 1995), to quantitate p53 protein in archival colorectal
cytosols.
The purpose of the present study was: (1) to evaluate the
relationship between p53 overexpression and clinicopathological
data and (2) to assess the value of p53 as a biological marker of
prognosis within each TNM class in a series of patients resected
for colorectal cancer with a long follow-up.
PATIENTS AND METHODS
Patients
A series of 111 patients underwent surgical resection for primary
colorectal adenocarcinoma at the II Department of Surgery,
University Hospital ￿San Carlos￿, Madrid, between 1990 and
1992. Each patient is regularly followed up at 6-monthly intervals
for a minimum of 5 years. Cases in which resections have been
performed for metachronous carcinoma, carcinoma arising in
familial adenomatous polyposis and ulcerative colitis are
excluded. None of the patients had received preoperative radio-
therapy or chemotherapy. Since 1992, stage III patients younger
than 70 received adjuvant chemotherapy with 5-fluorouracil
(5-FU) and leucovorin according to the prevailing protocol (four
patients). Clinical staging was done on the basis of the TNM
classification. Survival time was calculated from the date of
surgery to the date of death or last follow-up, with times censored
for patients dying of causes unrelated to colorectal cancer and
those surviving. Median follow-up was 5 years.
Tissue specimens
Sections from the colorectal adenocarcinoma and normal mucosa
at the proximal/distal resection margins were obtained at surgical
resection. These specimens were stored in liquid nitrogen and,
prior to being pulverized in the frozen state and homogenized for
the preparation of cytosols for protein measurement, cryostat
sections were evaluated; all tumour samples used contained more
than 80% tumour cells.
Luminometric assay
The LIA is based on a combination of two monoclonal antibodies,
Ab 1801 and DO 1, which detect both wild-type and mutant p53
protein in a sandwich-type assay. The Ab1801, which is immobi-
lized onto a solid phase, is used for catching. Ab DO 1, labelled
with a chemiluminescent compound (ABEI), is used for detection.
The immunoassay was performed by incubating either 100 ml of
p53 standard, controls or tumour cytosols, together with 100 ml of
the ABEI-conjugate in pre-coated tubes. After incubation for 18 h
at room temperature, unbound reagents were removed by washing
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Table 1 Relationship between p53 protein levels in colorectal tumours and clinicopathological variables
Variable n (%) p53 ³ 2.7 ng mg–1 p53 < 2.7 ng mg–1 P
Age 111 range: 31–89 (100) 27 (25) 84 (75)
Mean 66 years Mean 67 years Mean 66 years 1
Sex Male: 54 (49) 15 (27.8) 39 (72.2)
Female: 57 (51) 12 (21) 45 (79) 0.51
I: 14 (12.6) 3 (21.4) 11 (78.6)
Stage II: 50 (45) 11 (22) 39 (78)
III: 30 (27) 10 (33.3) 20 (66.7) 0.6
IV: 17 (15.3) 3 (17.6) 14 (82.4)
T status T1–T2: 17 (15) 5 (29.4) 12 (70.6)
T3–T4: 94 (85) 22 (23.4) 72 (76.6) 0.6
N status N0: 65 (58.6) 15 (23) 50 (77)
N+: 46 (41.4) 12 (26) 34 (74) 0.8
Right colon: 28 (25) 7 (25) 21 (75)
Site Left colon: 36 (33.4) 8 (22.2) 28 (77.8)  0.94
Rectum: 47 (39.6) 12 (25.5) 35 (74.5)
CEA <5 ng ml–1: 42 (42) 7 (16.7) 35 (83.3)
³5 ng ml–1: 58 (58) 18 (31) 40 (69) 0.16
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Figure 2. Stage III colorectal cancer patients. Overall survival curve according to p53 levels
Figure 1. Stage III colorectal cancer patients. Disease-free survival curve according to p53 levels124 E Adrover et al
British Journal of Cancer (1999) 81(1), 122–126 © 1999 Cancer Research Campaign
the tubes three times with 2 ml 0.9% sodium chloride. The chemi-
luminescent reaction was initiated by the sequential addition 
of 300 ml microperoxidase solution, immediately followed by
measurement of the chemiluminescent counts in a luminometer.
The p53 protein contents of the samples were determined from the
standard curve plotting the chemiluminescent response (in relative
light units (RLU)) against the standard concentrations of p53
protein. The detection limit was 0.01 ng p53 per ml sample. p53
concentration in the cytosols is expressed as ng mg—1 cytosolic
protein, the cytosol protein concentration being in the range
0.5—4 ng ml—1.
Statistical analyses
To evaluate the relationship between p53 expression and 
tumour behaviour, different cut-off values were tested and then 
2.7 ng mg—1 was selected as the cut-off value that yielded the best
discrimination of patients with good vs poor prognosis. Statistical
significance of differences was determined by the c2 or Fisher and
the Student￿s t-test or analysis of variance (ANOVA). Survival
rates were estimated by the Kaplan—Meier method and tested for
significance by the Breslow exact test, while multivariate compar-
isons were conducted using the Cox regression analysis. Stratified
analysis was used. Relative risks and their 95% confidence inter-
vals (CI) were calculated with the use of the estimated regression
coefficients and their standard errors. A P-value of < 0.05 was
considered significant. Analysis was performed using the SPSS
7.5 statistical software.
RESULTS
Survival data, available on all cases, showed a 7-year specific
overall survival of 49% (median 57 months). During follow-up, 37
patients had a relapse and 54 died from cancer-related deaths.
Fifteen patients died from other causes. The LIA revealed p53
overexpression only in 47 neoplastic samples (42.3%), while the
adjacent colonic mucosa was constantly negative. p53 values in
tumour cytosols ranged between 0 and 52 ng mg—1 protein, 75% of
the samples < 2.7 ng mg—1, with a mean value of 4.4 ng mg—1
protein. With regard to patient and tumour characteristics there
were no significant relationship between p53 levels and tumour
site, age, serum preoperative carcinoembryonic antigen (CEA)
levels, stage, nodal status or tumour invasion through the bowel
wall. Detailed information on patient and tumour characteristics is
given in Table 1 for each subset analysed.
Stratified analyses
Since tumour stage at diagnosis is the most powerful indicator of
clinical outcome in colorectal cancer patients, p53 expression
prognostic significance was assessed within each TNM class. Only
patients with stage III cancer whose tumours expressed high p53
levels had longer disease-free survival times than patients with
tumours lacking or with low-expressing LIA-detectable p53
protein (59.3% and 28.6% respectively) at a median follow-up of
60 months (P = 0.03). A longer overall survival (58.3% and 30%)
was also observed, although this finding did not reach statistical
significance (P = 0.09) (Figures 1 and 2).
Multivariate analyses
In multivariate analyses for relapse-free survival, including stan-
dard prognostic factors as covariates, p53 level < 2.7 ng mg—1 was
an independent factor for predicting the rate of relapse, with an
adjusted relative hazard rate of 2.13 (CI 0.89—5.07) (P = 0.05).
This association was independent of the TNM stage. However, p53
overexpression did not reach statistical significance for overall
survival.
Table 2 p53 immunohistochemical assays and prognosis in colorectal cancer
Reference Patients Follow-up p53 poor Multivariate analysis Yes/No and other
prognostic factor comments
Sun 1993 293 5 years Y MVA – yes. Nuclear and cytoplasmic p53
associated with adverse prognosis in I-III
stages
Yamaguchi 1992 100 6–48 months Y MVA – yes. 3-year survival significantly worse
for p53-expressing cases
Bell 1993 100 34 months N No MVA. No relationship of p53 and overall
survival
Yamaguchi 1993 203 5 years Y No MVA. P53-positive cases associated with
adverse survival
Auvinen 1994 144 9 years Y No MVA. Overall survival reduced in p53
positive cases
Nathanson 1994 84 > 5 years N MVA – yes. No relationship of p53 and overall
survival identified in stage II
Zeng 1994 107 62 months Y MVA – yes. Study conducted in stage III–IV
patients with low CEA levels
Mulder 1995 109 > 7 years N MVA – yes. P53 not an independent marker of
prognosis in all stages.
Ofner 1995 109 79 months N No MVA. p53 expression not an independent
marker of prognosis
Kressner 1996 294 4.5 years N MVA – yes. No relationship of p53 and overall
survival identified in all stages
Poller 1997 250 4.3 years N MVA – yes. No relationship of p53 and overall
survival identified in stage I–III tumoursp53 protein levels and survival in colorectal cancer 125
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DISCUSSION
A sensitive and quantitative LIA has been developed for the
measurement of wild-type and mutant p53 in extracts from tumour
tissue. The p53—LIA has been performed previously on breast
tumour cytosols (Borg et al, 1995) where it yielded reliable esti-
mates of p53 expression as compared with IHC analysis. This
novel immunoassay, although relatively time-consuming, allows
an exact quantification of p53 expression in a way that is superior
to IHC. In our series, p53 protein was detected in 42% of the
tumour samples; this is well in line with previously reported p53
IHC overexpression in colorectal carcinomas, ranging from 42 to
69% (Scott et al, 1991; Auvinen et al, 1994). We found no correla-
tion between p53 levels, tumour stage, site, serum preoperative
CEA levels, bowel wall invasion and nodal status. Similar results
have been reported previously (Scott et al, 1991; Starzynska et al,
1992; Bell et al, 1993; Nathanson et al, 1994; Mulder et al, 1995;
Poller et al, 1997). At least 30 investigations have dealt with the
prognostic significance of p53 aberrations in colorectal adeno-
carcinoma, providing contrasting results (Viale, 1997). In the vast
majority of these studies, IHC was used to document an abnormal
accumulation of p53 protein in neoplastic cells. The variables
related to the staining protocols and scoring systems are so
numerous that it is almost impossible to compare the results of
different studies. Table 2 lists some of the most relevant published
data on the prognostic value of p53 IHC expression in colorectal
cancer; most would suggest that expression of p53 is an adverse
prognostic factor. However, of the seven investigations using
multivariate analysis, three documented a significant inverse
correlation of p53 accumulation with patient survival, whereas
four did not.
To clarify the influence of p53 overexpression on long-term
survival in colorectal cancer patients, we performed LIA based on
a combination of two monoclonal antibodies, Ab1801 and DO 1,
which detects both wild-type and mutant p53 protein. No differ-
ence in survival was found between p53-positive and -negative
tumours in the whole series, so we used the cut-off value of 
2.7 ng mg—1 for survival analysis. The most important finding was
that high p53 level in the tumour cytosols was associated with
favourable disease-free survival (P = 0.45) in all stages, but not
significantly by univariate analysis. This survival advantage was
most apparent among stage III cancer patients. The multivariate
analyses confirmed that p53 expression was an independent prog-
nostic factor for time to progression when associations between
variables were accounted for (P = 0.05). As far as we are aware,
only two previous studies have directly correlated p53 accumula-
tion with prolonged survival in stage II—III colorectal cancer
patients (Soong et al, 1997; Ahnen et al, 1998); interestingly, the
survival advantage was more significant for stage III patients. In
two previous studies, this association appeared to become more
significant as the estimated percentage of cells staining positively
increased (Dix et al, 1994a); it was shown that IHC detection of
p53 protein does not always indicate the existence of an under-
lying mutation (Dix et al, 1994b). Other studies on non-small-cell
lung cancer (Lee et al, 1995), breast cancer (Sj￿gren et al, 1996)
and testis cancer (Eid et al, 1997) have observed the same unex-
pected favourable prognosis for patients with high p53 immuno-
staining. However, the organ and tissue of origin of the tumour
seems to have a crucial role in determining overall p53 function.
p53 overexpression is the end point of the action of many
different stabilizing mechanisms, which ultimately lead to p53
accumulation. LIA detects this overexpressed p53, without indi-
cating the mechanisms by which accumulation occurs. In the past,
it was assumed that only the mutant p53 protein, not the wild-type,
would be detected by IHC. This view was based on the observa-
tion that the wild-type p53 protein degrades rather rapidly, with 
a short half-life of 6—20 min, compared with most mutant p53
proteins, which have longer half-lives that range from 4 to 12
hours (Tominaga et al, 1992). However, clinical investigators have
observed that positive immunostaining does not always mean gene
mutation (Battifora, 1994). In addition, increases in wild-type p53
protein have been well documented in association with DNA
damage repair (Kastan et al, 1991) and after UV irradiation of
normal human skin (Campbell et al, 1993). Furthermore, not all
p53 mutations translate to positive immunostaining. Point muta-
tions leading to a stop codon, abnormal mRNA splicing, or gross
deletion or insertions are well-known cases in which immuno-
staining is negative despite gene mutations. These data are of
particular importance, because they imply that low levels of LIA
are not always indicative of a normal p53 gene status. More impor-
tantly, accumulating data indicate that not all mutant p53 proteins
lose the normal p53 functions, and the function of the mutant p53
gene product is variable depending on the mutation locus (Cho
et al, 1994; Levine et al, 1994). Recent studies have associated a
poor prognosis for colon cancer with specific p53 mutation
(B¿rresen-Dale et al, 1998). The higher rates of elevated p53
levels we have detected in stage III colorectal tumours could
explain such an observed better prognosis, but as we have not
screened our population of patients for p53 gene mutations, we
cannot rule out the genetic factors responsible for this. Whether
the tumours of this subset of patients have normal p53 or muta-
tions which retain wild-type function, rendering the tumours less
aggressive, remains to be studied.
In summary, it appears from our study that p53 protein over-
expression may tell us more about the functional status of the p53
control pathway than the presence of a mutation within the gene.
While the exact relationship between p53 gene mutation and
protein overexpression in tumours is determined, quantification of
p53 protein levels may be a useful parameter to optimize treatment
for patients with completely resected colorectal cancer.
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